arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CYTOKINETICS INC

CYTK
$65.80 ▼ -1.82 (-2.69%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
78 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

CYTOKINETICS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $8.7M
Dividend Yield
Revenue Growth -57.1%
Op. Margin None
ROIC -189.4%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -1.43
info Valuation on last close. End-of-day price, Sep 23, 2026.

78-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$28.62M
↓ -57.1%
Net Income Profit after all expenses
$-206.03M
↓ -27.7%
Operating Margin Operating profit as % of sales
-167.0%
↓ -1266.4%
Long-Term Debt Long-term obligations
$248.20M
— +0.4%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Financial Health
64
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 28 years · 78 quarters